ImmuPharma (LON:IMM) Trading 19.8% Higher - Time to Buy?

Key Points

• Shares of ImmuPharma plc increased by 19.8%, closing at GBX 12.99 ($0.18) after trading as high as GBX 13.45 during the day.
• The company's market cap stands at approximately £69.86 million with a very high P/E ratio of -1,570.67.
• ImmuPharma is focused on developing peptide-based therapeutics for autoimmune diseases, including its lead program, P140 (Lupuzor™), aimed at treating Lupus.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) rose 19.8% on Friday . The stock traded as high as GBX 13.45 ($0.18) and last traded at GBX 12.99 ($0.18). Approximately 27,507,469 shares changed hands during trading, an increase of 243% from the average daily volume of 8,022,162 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Stock Performance

The firm has a 50 day moving average price of GBX 2.88 and a two-hundred day moving average price of GBX 2.86. The company has a market cap of £69.86 million, a P/E ratio of -1,570.67 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, sell-side analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.